Edition:
United Kingdom

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

89.75SEK
4:29pm GMT
Change (% chg)

-0.25kr (-0.28%)
Prev Close
90.00kr
Open
90.00kr
Day's High
91.00kr
Day's Low
88.50kr
Volume
25,580
Avg. Vol
162,379
52-wk High
131.00kr
52-wk Low
84.00kr

Latest Key Developments (Source: Significant Developments)

Recipharm Q3 EBITDA down at SEK ‍103​ mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) :Q3 NET SALES SEK ‍1.20 BILLION VERSUS SEK 1.14 BILLION YEAR AGO.Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO.  Full Article

Recipharm Q3 EBITDA down at SEK ‍103​ mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) ::Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO.Q3 NET SALES SEK ‍1.20​ BILLION VERSUS SEK 1.14 BILLION YEAR AGO.  Full Article

Recipharm to end operations in two facilities in Sweden
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) ::RECIPHARM TO END OPERATIONS IN TWO FACILITIES IN SWEDEN.‍TO START A PROCESS WITH INTENTION OF DISCONTINUING ACTIVITIES BOTH IN STOCKHOLM AND HÖGANÄS.​.‍WILL EXPLORE OPPORTUNITY TO CLOSE FACILITIES DURING SECOND HALF OF 2019​.SAYS ‍WILL EVALUATE DIFFERENT OPTIONS FOR FACILITY SUCH AS DIVESTMENT OF MANUFACTURING SITE​.‍FINAL DECISION REGARDING DISCONTINUED MANUFACTURING OPERATIONS IN STOCKHOLM AND HÖGANÄS TO BE MADE BEFORE END-2017.‍CLOSURE AFFECTS APPROXIMATELY 225 OF SWEDISH EMPLOYEES​.‍WILL EXPLORE OPPORTUNITY TO CLOSE FACILITIES IN GREATER STOCKHOLM AREA DURING SECOND HALF OF 2019​.‍ESTIMATED NON-RECURRING COSTS ASSOCIATED WITH DECISION TO DISCONTINUE OPERATIONS ARE EXPECTED TO BE CHARGED TO Q4​.‍ESTIMATED NON-RECURRING COSTS ASSOCIATED WITH DECISION TO BE CHARGED TO Q4 RESULTS​.  Full Article

Recipharm says Chief Financial Officer to leave company
Monday, 19 Dec 2016 

Recipharm Ab (Publ) : Says Chief Financial Officer to leave recipharm .Says a search process has commenced to appoint a new CFO..  Full Article

Recipharm places SEK 1,000 mln convertible bonds
Thursday, 29 Sep 2016 

Recipharm Ab (Publ) : Says places SEK 1,000 million senior unsecured convertible bonds .Says the bonds will carry a coupon of 2.75 pct per annum, and have a conversion price set at SEK 181.955.  Full Article

Recipharm H1 EBITDA up 20 pct
Friday, 22 Jul 2016 

Recipharm Publ Ab : Jan-Jun net sales amounted to sek 2 208 million (1 742), an increase of 27 % . Jan-Jun ebitda increased by 20 % and amounted to sek 376 million (314) giving an ebitda margin of 17.0 % (18.0) . Says going forward i expect our growth-driving strategies, including executing on further acquisition opportunities, to continue to deliver Further company coverage: [RECIb.ST] (Reporting By Johan Ahlander) ((johan.ahlander@thomsonreuters.com;)).  Full Article

Recipharm creates global CDMO leader through SEK 1.7 bln acquisitions
Monday, 18 Apr 2016 

Recipharm publ AB:Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India.Recipharm says signed two separate agreements to acquire Kemwell's pharmaceutical contract development and manufacturing (cdmo) businesses.Recipharm says proposed share issue of approximately sek 850 million with preferential rights for existing shareholders.Recipharm says businesses to be acquired had 2015 preliminary net sales of approximately sek 745 million, corresponding to 22 per cent of Recipharm's 2015 total net sales.Recipharm says acquisitions are expected to be accretive to ebitda margin already from 2016 and are well in line with Recipharm's overall financial objectives.The acquisition price for Kemwell's operations in the US and Sweden amounts to approximately USD 85 million (SEK 693 million) on a cash and debt free basis.Closing of the transaction is expected to take place during the second quarter of 2016.The acquisition price for the operations in India amounts to USD 120 million (SEK 982 million) on a cash and debt free basis.  Full Article

Recipharm publ AB prposes a dividend for FY 2015, sets new objectives
Wednesday, 24 Feb 2016 

Recipharm publ AB:Proposed share dividend is 1.50 (1.25) crown per share​ for FY 2015.New objectives are to reach sales of at least 8 billion crowns by 2020, to have an EBITDA margin of at least 16 pct and to have a net debt to equity ratio less than 0.8​.Objective that 30-50 pct of profit after tax should be distributed as dividend to shareholders remains unchanged​.  Full Article

Recipharm publ AB to acquire Mitim Srl
Tuesday, 23 Feb 2016 

Recipharm publ AB:Recipharm to acquire Italian Mitim Srl for 640 million crowns adding scale and niche technology in injectable beta lactams.The transaction is valued to an Enterprise Value of 68 million euros (640 million crowns) equivalent to about 8 times pro forma 2015 EBITDA.Transaction costs of about 4 million crowns will be charged to Q1 results.  Full Article

Recipharm plans to invest EUR 40 mln over three years in new serialisation processes
Wednesday, 10 Feb 2016 

Recipharm publ AB:Says plans to invest 40 million euros over the next three years to ensure state-of-the-art solutions for serialisation processes.  Full Article

BRIEF-Recipharm commences new supply contract

* RECIPHARM COMMENCES NEW SUPPLY CONTRACT AND COMPLETES PURCHASE OF FACILITY IN SPAIN Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)